Stock listing

Dusseldorf:8NE Lisata Therapeutics, Inc. Aktie

German listing (Dusseldorf) of Lisata Therapeutics, Inc. · home listing NASDAQ:LSTA

Follow Lisata Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:LSTA

$0.899 USD -0.081 (-8.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:LSTA

Past year -54.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.850 – $0.900 USDNov 20, 2026
Volume
139,259 sharesNov 20, 2026
Market cap
$9.71M USDAt the close on Nov 20, 2026 · price × 10.80M shares outstanding
52-week range
$0.850 – $5.070 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$460,210 USDMedian day 96,293 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lisata Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LSTA · Home$0.899 USD-0.081 (-8.3%)139,259$0.883$0.900$0.850$0.980Close on Nov 20, 2026
LSE:0HS8$0.925 USD-0.061 (-6.2%)4,034$0.950$0.967$0.910$0.987Close on Nov 19, 2026
Frankfurt:8NE€0.70 EUR-0.035 (-4.8%)—€0.70€0.70€0.70€0.735Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LSTA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.899-0.081-8.3%$0.883$0.900$0.850139,259
$0.980-0.060-5.8%$1.050$1.105$0.892222,092
$1.040-0.050-4.6%$1.080$1.100$1.000246,917
$1.090-0.120-9.9%$1.160$1.220$1.04044,987
$1.210-0.070-5.5%$1.250$1.260$1.200104,863
$1.280+0.080+6.7%$1.210$1.300$1.150119,688
$1.200+0.180+17.6%$1.030$1.430$1.0301,061,414
$1.020-0.100-8.9%$1.090$1.090$1.01020,347
$1.120+0.090+8.7%$1.060$1.210$0.985292,876
$1.030+0.038+3.9%$1.020$1.060$0.99015,114
$0.992-0.069-6.5%$1.060$1.069$0.99263,267
$1.060-0.030-2.8%$1.063$1.105$1.06013,622
$1.090+0.080+7.9%$1.010$1.090$1.01029,512
$1.010-0.010-1.0%$1.080$1.148$1.00097,147
$1.020+0.010+1.0%$0.990$1.090$0.99060,778
$1.010-0.050-4.7%$1.040$1.120$0.99027,843
$1.060+0.040+3.9%$1.010$1.120$1.01075,391
$1.020-0.040-3.8%$1.040$1.040$1.01040,773
$1.060+0.064+6.4%$0.980$1.060$0.96160,317
$0.996-0.009-0.9%$1.000$1.010$0.97045,557
$1.005-0.045-4.3%$1.060$1.060$1.00027,668
$1.050+0.010+1.0%$1.050$1.070$1.01045,570
$1.040+0.040+4.0%$1.000$1.080$0.996113,743
$1.000-0.030-2.9%$1.030$1.040$0.96096,293
$1.030-0.040-3.7%$1.040$1.070$1.02057,126
$1.070+0.050+4.9%$1.050$1.070$1.00023,166
$1.020-0.060-5.6%$1.000$1.070$0.99680,257
$1.080+0.030+2.9%$1.100$1.150$0.990146,856
$1.050-0.010-0.9%$1.040$1.060$0.980166,669
$1.060-0.140-11.7%$1.280$1.280$1.020280,231
$1.200+0.030+2.6%$1.220$1.310$1.130704,822
$1.170-0.040-3.3%$1.220$1.220$1.16013,582
$1.210-0.050-4.0%$1.310$1.320$1.140124,181
$1.260-0.210-14.3%$1.450$1.475$1.26090,753
$1.470-0.020-1.3%$1.490$1.500$1.4703,681
$1.490+0.050+3.5%$1.420$1.560$1.42063,138
$1.440-0.030-2.0%$1.470$1.500$1.43517,080
$1.470-0.030-2.0%$1.480$1.536$1.44050,722
$1.500-0.080-5.1%$1.560$1.570$1.50038,184
$1.580+0.080+5.3%$1.540$1.580$1.49047,897
$1.500+0.065+4.5%$1.470$1.530$1.43525,475
$1.435-0.045-3.0%$1.460$1.500$1.40077,241
$1.480-0.080-5.1%$1.550$1.600$1.440152,755
$1.560-0.140-8.2%$1.640$1.650$1.540228,887
$1.700-0.040-2.3%$1.710$1.760$1.610293,908
$1.740+0.270+18.4%$2.500$2.560$1.5003,043,749
$1.470-0.070-4.5%$1.530$1.570$1.47093,541
$1.540-0.020-1.3%$1.530$1.560$1.430157,865
$1.560-0.070-4.3%$1.680$1.680$1.455169,191
$1.630-0.010-0.6%$1.720$1.720$1.567111,886
$1.640-0.260-13.7%$1.915$1.915$1.538236,640
$1.900+0.040+2.2%$1.860$1.999$1.730208,266
$1.860+0.210+12.7%$1.650$1.890$1.620252,498
$1.650+0.010+0.6%$1.580$1.700$1.56433,923
$1.640+0.070+4.5%$1.570$1.710$1.450162,868
$1.5700.0000.0%$1.520$1.640$1.450113,611
$1.570+0.080+5.4%$1.480$1.640$1.234475,598
$1.490-0.200-11.8%$1.660$1.660$1.440243,389
$1.690-0.130-7.1%$1.800$1.815$1.540245,048
$1.820+0.010+0.6%$1.760$1.940$1.76086,666
$1.810+0.070+4.0%$1.760$1.870$1.75051,731
$1.740-0.020-1.1%$1.750$1.900$1.720184,299
$1.760+0.210+13.5%$1.630$2.000$1.6001,094,249
$1.550+0.430+38.4%$1.110$1.790$1.1047,120,557
$1.1200.0000.0%$1.130$1.165$1.07094,818

Splits

5 splits since 2006 · NASDAQ:LSTA · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-10Consolidation
1-for-10Consolidation
1-for-10Consolidation
1-for-10Consolidation
Ticker
Dusseldorf:8NE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Lisata Therapeutics, Inc. news

Lisata Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 36 in all · newest Nov 19, 2026 · oldest 2025
Calls
13 calls with a replay · 13 with a transcript · latest Nov 6, 2025
Decks
93 decks · latest November 2026

Where Lisata Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LSTA · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A3DWGCLang & SchwarzGermanyEUR
LS Exchange:A3DWGCLS ExchangeGermanyEUR
Munich:8NEMunichGermanyEUR
gettex:8NEgettexGermanyEUR
LSE:0HS8LSEUnited KingdomUSD
BOATS:LSTABOATSUnited StatesUSD
Dusseldorf:8NE · This pageDusseldorfGermanyEUR
Frankfurt:8NEFrankfurtGermanyEUR
Stuttgart:8NEStuttgartGermanyEUR
Tradegate:8NETradegateGermanyEUR

Valuation

EV/sales −2,730× against a median of −5.9×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$273.0M USD
P/E
Loss
EV/sales
−2,730×
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
0.71

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lisata Therapeutics, Inc. · NASDAQ:LSTAUS$9.71M−US$273.0Mn/a−2,730×n/a1.3×n/a0.0×0.71
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
aTyr Pharma, Inc. · NASDAQ:ATYRUS$9.74M−US$28.09Mn/an/an/a0.3×n/a0.3×2.12
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Alzinova AB · OMXSTO:ALZUS$9.58MUS$8.35Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
Median of the othersUS$9.58MUS$4.33M0.1×−5.9×0.6×−303.7%0.0×1.35

Forecasts

2 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.09 · 1 analyst

Team and board

Officers

OfficerRole
David J. MazzoPresident and Chief Executive Officer
Tariq ImamSenior Vice President, Business Development and Operations and General Counsel
John MendittoVice President, Investor Relations and Corporate Communications
James NiscoSenior Vice President, Finance and Treasury and Chief Accounting Officer

Board

DirectorRole
Gregory B. BrownChairman
Cynthia L. FlowersDirector
Heidi HensonDirector
Jeff FarrowDirector
Mohammad AzabDirector
Steven M. KloskDirector

Events

Results days

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−9.9%
Q2 2026Aug 20, 2026+38.4%
Q1 2026May 7, 2026−3.4%
Q4 2025Feb 26, 2026−6.6%
Q3 2025Nov 6, 2025 · After close−12.3%
Q2 2025Aug 7, 2025 · After close−7.1%
Q1 2025May 8, 2025 · After close−11.6%
Q4 2024Feb 26, 2025 · After close+0.4%
Q3 2024Nov 12, 2024 · After close−4.1%
Q2 2024Aug 12, 2024 · After close+0.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close+1.3%
Q4 2023Feb 29, 2024 · After close+5.8%
Q3 2023Nov 2, 2023 · After close+8.3%
Q2 2023Aug 14, 2023 · After close0.0%
Q1 2023May 9, 2023 · After close−0.5%
Q4 2022Mar 30, 2023 · After close+2.0%
Q3 2022Nov 10, 2022 · After close0.0%
Q2 2022Aug 4, 2022 · After close−1.9%
Q1 2022May 5, 2022 · After close−10.1%
Q4 2021Mar 22, 2022 · After close−2.0%

Open Events

Decks

DeckKindSlidesDate
Marea Therapeutics — Investor Presentation (November 2026)Investor deck22 slidesNovember 2026
Merger or Acquisition (September 2026)Merger or acquisition28 slidesSep 17, 2026
Marea Therapeutics — Investor Presentation (September 2026)Investor deck25 slidesSeptember 2026
Investor Presentation (November 2025)Investor deck78 slidesNov 6, 2025
Investor Presentation (October 2025)Investor deck70 slidesOct 14, 2025
Q2 2025 Earnings PresentationEarnings71 slidesAug 7, 2025
Investor Presentation (June 2025)Investor deck70 slidesJun 26, 2025
Investor Presentation (June 2025)Investor deck65 slidesJun 17, 2025
Investor Presentation (May 2025)Investor deck56 slidesMay 8, 2025
Investor Presentation (February 2025)Investor deck56 slidesFeb 27, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (January 2025)Investor deck56 slidesJan 23, 2025
Investor Presentation (November 2024)Investor deck53 slidesNov 12, 2024
Investor Presentation (August 2024)Investor deck50 slidesAug 12, 2024
Investor Presentation (May 2024)Investor deck53 slidesMay 9, 2024
Investor Presentation (February 2024)Investor deck51 slidesFeb 29, 2024
Investor Presentation (November 2023)Investor deck51 slidesNov 2, 2023
Investor Presentation (August 2023)Investor deck54 slidesAug 14, 2023
Investor Presentation (May 2023)Investor deck57 slidesMay 9, 2023
Investor Presentation (March 2023)Investor deck51 slidesMar 30, 2023
Investor Presentation (February 2023)Investor deck57 slidesFeb 6, 2023
Investor Presentation (November 2022)Investor deck36 slidesNov 10, 2022
Investor Presentation (September 2022)Investor deck35 slidesSep 22, 2022
Caladrius Biosciences — Merger or Acquisition (August 2022)Merger or acquisition17 slidesAug 15, 2022
Caladrius Biosciences — Merger or Acquisition (August 2022)Merger or acquisition42 slidesAug 5, 2022
Caladrius Biosciences — Merger or Acquisition (May 2022)Merger or acquisition42 slidesMay 23, 2022
Caladrius Biosciences — Merger or Acquisition (May 2022)Merger or acquisition37 slidesMay 5, 2022
Caladrius Biosciences — Merger or Acquisition (April 2022)Merger or acquisition24 slidesApr 27, 2022
Caladrius Biosciences — Investor Presentation (March 2022)Investor deck33 slidesMar 22, 2022
Caladrius Biosciences — Investor Presentation (November 2021)Investor deck34 slidesNov 4, 2021
Caladrius Biosciences — Investor Presentation (August 2021)Investor deck34 slidesAug 5, 2021
Caladrius Biosciences — Investor Presentation (May 2021)Investor deck37 slidesMay 6, 2021
Caladrius Biosciences — Investor Presentation (February 2021)Investor deck37 slidesFeb 25, 2021
Caladrius Biosciences — Investor Presentation (January 2021)Investor deck37 slidesJan 11, 2021
Caladrius Biosciences — Investor Presentation (December 2020)Investor deck39 slidesDec 14, 2020
Caladrius Biosciences — Investor Presentation (March 2020)Investor deck38 slidesMar 5, 2020
Technical Presentation (2020)Technical16 slides2020
Caladrius Biosciences — Investor Presentation (November 2019)Investor deck38 slidesNov 18, 2019
Caladrius Biosciences — Investor Presentation (April 2019)Investor deck32 slidesApr 11, 2019
Caladrius Biosciences — Investor Presentation (April 2019)Investor deck31 slidesApr 11, 2019
Caladrius Biosciences — Investor Presentation (March 2018)Investor deck29 slidesMar 14, 2018
Caladrius Biosciences — Investor Presentation (June 2017)Investor deck30 slidesJun 5, 2017
Caladrius Biosciences — Investor Presentation (April 2017)Investor deck6 slidesApr 27, 2017
Caladrius Biosciences — Investor Presentation (March 2017)Investor deck35 slidesMar 22, 2017
Caladrius Biosciences — Investor Presentation (November 2016)Investor deck26 slidesNov 7, 2016
Caladrius Biosciences — Investor Presentation (October 2016)Investor deck26 slidesOct 19, 2016
Caladrius Biosciences — Investor Presentation (March 2016)Investor deck27 slidesMar 17, 2016
Caladrius Biosciences — Investor Presentation (January 2016)Investor deck28 slidesJan 11, 2016
Caladrius Biosciences — Investor Presentation (August 2015)Investor deck38 slidesAug 6, 2015
NeoStem — Technical Presentation (March 2015)Technical22 slidesMar 16, 2015
NeoStem — Investor Presentation (March 2015)Investor deck40 slidesMar 16, 2015

This page holds 50 of 93 decks. Open Decks

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue170.0K1.00M00000035.3M
Cost of revenue146.0K174.0K189.0K69.0K55.0K63.0K65.0K225.0K372.0K31.1M
Gross profit24.0K1.00M-189.0K63.8M-55.0K-63.0K-65.0K-225.0K-372.0K4.15M
Research and development7.95M11.3M12.7M13.1M17.7M9.25M10.8M7.59M15.8M16.7M
Selling, general and administrative10.4M12.1M13.0M14.1M11.5M9.89M9.29M9.39M11.8M12.8M
Operating income-18.2M-22.4M-25.7M-57.6M-29.1M-19.1M-20.1M-17.0M-27.6M-29.5M
Depreciation and amortization146.0K174.0K189.0K69.0K55.0K100.0K100.0K200.0K400.0K500.0K
EBITDA-18.1M-22.2M-25.5M-57.5M-29.0M-19.0M-20.0M-16.8M-27.2M-29.0M
Interest expense1.95M227.0K123.0K05.00K378.0K1.78M
Income before tax-17.5M-20.8M-23.2M-56.7M-29.0M-19.0M-19.4M-16.2M-27.7M-31.3M
Income tax-962.0K-798.0K-2.33M-2.48M-1.51M-10.9M00-11.5M0
Net income-16.6M-20.0M-20.8M-54.2M-27.5M-8.15M-19.4M-16.2M23.0M-32.7M
Earnings per share, basic-1.91-2.40-2.58-10.47-7.45-0.53-1.88-1.672.56-4.99
Earnings per share, diluted-1.91-2.40-2.58-10.47-7.45-0.53-1.88-1.672.56-4.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents16.0M16.2M22.6M32.2M24.6M16.5M14.0M10.3M29.2M7.08M
Short-term investments015.0M27.9M37.1M70.3M18.1M11.1M32.8M25.9M
Receivables0900.0K0234.5K138.8K
Inventory5.00M3.58M
Current assets17.7M34.6M53.9M71.9M96.2M35.3M26.0M44.1M61.4M24.6M
Property, plant and equipment18.0K72.0K175.0K296.0K62.0K57.0K100.0K165.0K257.0K705.4K
Goodwill07.01M
Total assets17.7M35.0M54.7M73.0M97.0M36.0M27.2M44.6M63.4M53.5M
Accounts payable1.02M1.28M2.42M2.65M1.93M1.02M1.49M762.0K1.34M2.23M
Current liabilities3.07M5.61M6.59M6.38M4.52M3.51M5.98M5.62M9.31M21.2M
Long-term debt02.52M
Total debt137.0K168.0K485.0K714.0K624.0K978.0K05.65M
Total liabilities3.14M5.68M6.80M6.71M5.01M3.76M6.60M7.13M13.2M30.0M
Shareholders' equity14.9M29.6M48.1M66.6M92.3M32.5M20.8M37.7M50.5M4.88M
Shares outstanding8.83M8.41M8.15M7.87M3.99M19.4M10.5M9.87M9.48M8.21M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-15.9M-19.4M-20.0M-21.2M-22.2M-8.82M-18.9M-20.0M-20.9M-23.7M
Capital spending-28.0K00-285.0K-60.0K-20.0K0-134.0K-135.0K-1.10M
Free cash flow-16.0M-19.4M-20.0M-21.5M-22.3M-8.84M-18.9M-20.1M-21.0M-24.8M
Cash from investing15.1M13.2M10.1M28.9M-54.9M-7.28M21.4M-4.71M41.3M-2.85M
Cash from financing599.0K-206.0K385.0K-224.0K85.3M18.6M1.18M824.0K-932.0K20.9M
Dividends paid-15.0M
Share buybacks-91-267-248-148-130-403-358-72
Change in cash-253.0K-6.38M-9.56M7.51M8.13M2.48M3.73M-23.9M19.5M-5.61M

Open Financials

Filings

FilingDateTypeFiled with
S-3/A · Registration statement, amendedNov 19, 2026Offer documentSEC
8-K/A · Current report, amendedNov 19, 2026Current reportSEC
8-K · Current reportNov 19, 2026Current reportSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
S-3 · Registration statementNov 12, 2026Offer documentSEC
S-8 · Registration statement for employee plansNov 12, 2026Offer documentSEC
8-K/A · Current report, amendedNov 12, 2026Current reportSEC
DEFA14A · Additional proxy materialNov 9, 2026Meeting noticeSEC
8-K · Current reportNov 9, 2026Management or board changeSEC
ARS · Annual report to shareholdersOct 19, 2026Annual reportSEC
Show 200 filings
FilingDateTypeFiled with
DEF 14A · Proxy statementOct 19, 2026Meeting noticeSEC
3 · Initial statement of ownershipOct 15, 2026Insider tradeSEC
8-K · Current reportOct 14, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementOct 7, 2026Meeting noticeSEC
DOct 2, 2026Other filingsSEC
3 · Initial statement of ownershipSep 28, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 28, 2026Insider tradeSEC
8-K · Current reportSep 17, 2026Acquisition or disposalSEC
SCHEDULE 13G · Big-stake noticeAug 26, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026Management or board changeSEC
SC TO-T/AJul 28, 2026Acquisition or disposalSEC
8-K · Current reportJul 24, 2026Current reportSEC
SC 14D9/AJul 21, 2026Acquisition or disposalSEC
8-K · Current reportJul 17, 2026Material contractSEC
SC 14D9/AJul 17, 2026Acquisition or disposalSEC
SC TO-T/AJul 17, 2026Acquisition or disposalSEC
SC 14D9/AJul 13, 2026Acquisition or disposalSEC
SC TO-T/AJul 10, 2026Acquisition or disposalSEC
SC 14D9/AJul 2, 2026Acquisition or disposalSEC
SC 14D9Jun 10, 2026Acquisition or disposalSEC
SC TO-TJun 10, 2026Acquisition or disposalSEC
SC14D9CJun 9, 2026Other filingsSEC
8-K · Current reportJun 9, 2026Material contractSEC
SC TO-CJun 1, 2026Other filingsSEC
SC14D9CJun 1, 2026Other filingsSEC
8-K · Current reportJun 1, 2026Current reportSEC
SC TO-CMay 29, 2026Other filingsSEC
SC14D9CMay 29, 2026Other filingsSEC
8-K · Current reportMay 29, 2026Material contractSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
SC TO-CMay 4, 2026Other filingsSEC
SC14D9CMay 4, 2026Other filingsSEC
8-K · Current reportMay 4, 2026Material contractSEC
10-K/A · Annual report, amendedApr 28, 2026Annual reportSEC
SC14D9CApr 15, 2026Other filingsSEC
8-K · Current reportApr 15, 2026Current reportSEC
SC14D9CApr 2, 2026Other filingsSEC
8-K · Current reportApr 2, 2026Current reportSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
SC14D9CMar 9, 2026Other filingsSEC
8-K · Current reportMar 9, 2026Material contractSEC
SC14D9CFeb 27, 2026Other filingsSEC
8-K · Current reportFeb 27, 2026Material contractSEC
8-K · Current reportJan 27, 2026Current reportSEC
SC14D9CJan 21, 2026Other filingsSEC
8-K · Current reportJan 21, 2026Material contractSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJan 8, 2026Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 14, 2025Current reportSEC
8-K · Current reportOct 8, 2025Material contractSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
8-K · Current reportJul 15, 2025Current reportSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportJun 17, 2025ResultsSEC
8-K · Current reportJun 13, 2025Management or board changeSEC
8-K · Current reportJun 10, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
3 · Initial statement of ownershipFeb 5, 2025Insider tradeSEC
8-K · Current reportJan 23, 2025Current reportSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
8-K · Current reportDec 3, 2024Material contractSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
424B5 · ProspectusAug 21, 2024Offer documentSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
S-8 · Registration statement for employee plansJul 15, 2024Offer documentSEC
8-K · Current reportJun 27, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 10, 2024Other filingsSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
CORRESP · Letter to the SECMay 7, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 6, 2024Other filingsSEC
S-3 · Registration statementMay 1, 2024Offer documentSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
3 · Initial statement of ownershipApr 24, 2024Insider tradeSEC
8-K · Current reportApr 17, 2024Management or board changeSEC
ARS · Annual report to shareholdersMar 28, 2024Annual reportSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
4 · Change in ownershipJan 12, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
4 · Change in ownershipJan 11, 2024Insider tradeSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
4 · Change in ownershipSep 5, 2023Insider tradeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
S-8 · Registration statement for employee plansJul 13, 2023Offer documentSEC
8-K · Current reportJul 11, 2023Management or board changeSEC
8-K · Current reportJun 14, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
8-K · Current reportMay 9, 2023ResultsSEC
DEFA14A · Additional proxy materialMay 1, 2023Meeting noticeSEC
DEF 14A · Proxy statementMay 1, 2023Meeting noticeSEC
8-K · Current reportMay 1, 2023Management or board changeSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
8-K · Current reportFeb 6, 2023ResultsSEC
4 · Change in ownershipJan 17, 2023Insider tradeSEC
4 · Change in ownershipJan 12, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
4 · Change in ownershipJan 11, 2023Insider tradeSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
S-8 · Registration statement for employee plansOct 17, 2022Offer documentSEC
8-K/A · Current report, amendedOct 14, 2022Current reportSEC
8-K/A · Current report, amendedOct 4, 2022Current reportSEC
8-K · Current reportSep 29, 2022Current reportSEC
424B5 · ProspectusSep 26, 2022Offer documentSEC
8-K · Current reportSep 22, 2022Current reportSEC
3 · Initial statement of ownershipSep 16, 2022Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2022Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2022Insider tradeSEC
4 · Change in ownershipSep 16, 2022Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2022Insider tradeSEC
8-K · Current reportSep 15, 2022Acquisition or disposalSEC
8-K · Current reportSep 14, 2022Meeting outcomeSEC
4 · Change in ownershipSep 2, 2022Insider tradeSEC
4 · Change in ownershipSep 2, 2022Insider tradeSEC
425Sep 2, 2022Other filingsSEC
8-K · Current reportAug 19, 2022Current reportSEC
425Aug 15, 2022Other filingsSEC
425Aug 10, 2022Other filingsSEC
8-K · Current reportAug 5, 2022ResultsSEC
10-Q · Quarterly reportAug 4, 2022Quarterly reportSEC
424B3 · ProspectusJul 29, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 29, 2022Other filingsSEC
CORRESP · Letter to the SECJul 26, 2022Other filingsSEC
S-4/A · Registration statement, amendedJul 26, 2022Offer documentSEC
425Jul 6, 2022Other filingsSEC
S-4 · Registration statementJun 15, 2022Offer documentSEC
425Jun 9, 2022Other filingsSEC
8-K · Current reportMay 23, 2022Current reportSEC
10-Q · Quarterly reportMay 5, 2022Quarterly reportSEC
8-K · Current reportMay 5, 2022ResultsSEC
425Apr 27, 2022Other filingsSEC
8-K · Current reportApr 27, 2022Material contractSEC
10-K/A · Annual report, amendedApr 21, 2022Annual reportSEC
10-K · Annual reportMar 22, 2022Annual reportSEC
8-K · Current reportMar 22, 2022ResultsSEC
8-K · Current reportFeb 25, 2022Management or board changeSEC
8-K · Current reportFeb 18, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 3, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 19, 2022Big-stake noticeSEC
4 · Change in ownershipJan 18, 2022Insider tradeSEC
4 · Change in ownershipJan 18, 2022Insider tradeSEC
4 · Change in ownershipJan 12, 2022Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Lisata Therapeutics, Inc.’s releases

Common shares
10,804,066
Fully diluted
10,804,066

Fully diluted

LineShares
Common shares10,804,066

Share count over time

CountShares
Nov 22, 202610,804,066
Nov 19, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Adage Capital Partners Gp, L.L.C.2.49M23.0%US$3.58MSep 30, 2026
Trv Gp V, LLC455K4.2%US$655KSep 30, 2026
Seven Fleet Capital Management LP371K3.4%US$535KSep 30, 2026
Vanguard329K3.0%US$474KSep 30, 2026
Fcpm III Services B.V.297K2.8%US$428KSep 30, 2026
Alpha Wave Global, LP183K1.7%US$264KSep 30, 2026
venBio Partners LLC156K1.4%US$225KSep 30, 2026
Sofinnova Investments, Inc.156K1.4%US$225KSep 30, 2026
Yakira Capital Management, Inc.136K1.3%US$195KSep 30, 2026
Nantahala Capital Management, LLC101K0.94%US$146KSep 30, 2026
All 37 holders
HolderSharesOf the companyValueAs of
Citadel76,2750.71%US$110KSep 30, 2026
Geode Capital72,6320.67%US$105KSep 30, 2026
Deltec Asset Management LLC63,1970.58%US$91,004Sep 30, 2026
BlackRock54,8570.51%US$78,994Sep 30, 2026
Trv Gp VI, LLC48,4460.45%US$69,762Sep 30, 2026
Css LLC41,2220.38%US$59,360Sep 30, 2026
Gts Securities LLC35,5000.33%US$51,120Sep 30, 2026
Virtu Financial LLC34,4350.32%US$50,000Sep 30, 2026
Jane Street28,1420.26%US$40,524Sep 30, 2026
State Street25,3480.23%US$36,501Sep 30, 2026
Two Sigma18,0830.17%US$26,040Sep 30, 2026
Northern Trust14,4650.13%US$20,830Sep 30, 2026
UBS13,5790.13%US$19,553Sep 30, 2026
FNY Investment Advisers, LLC13,0000.12%US$18,000Sep 30, 2026
Cerity Partners LLC12,1830.11%US$17,544Sep 30, 2026
Bank of America10,3530.10%US$14,908Sep 30, 2026
HighTower Advisors, LLC10,0420.09%US$14,460Sep 30, 2026
RBC718<0.01%US$1,000Sep 30, 2026
Osaic Holdings, Inc.250<0.01%US$360Sep 30, 2026
Morgan Stanley75<0.01%US$108Sep 30, 2026
Fidelity8<0.01%US$12Sep 30, 2026
SBI Securities Co., Ltd.7<0.01%US$10Sep 30, 2026
Caitong International Asset Management Co., Ltd4<0.01%US$6Sep 30, 2026
Cheviot Value Management, LLC3<0.01%US$4Sep 30, 2026
Barclays2<0.01%US$3Sep 30, 2026
Fortitude Family Office, LLC1<0.01%US$1Sep 30, 2026
Citigroup Inc1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund191K1.8%US$651KJun 30, 2026
Vanguard Extended Market Index Fund80,4440.74%US$274KJun 30, 2026
Fidelity Extended Market Index Fund39,0030.36%US$127KMay 31, 2026
Fidelity Series Total Market Index Fund10,3730.10%US$33,712May 31, 2026
Vanguard Balanced Index Fund7,0220.06%US$23,875Jun 30, 2026
Fidelity Total Market Index Fund4,3790.04%US$14,232May 31, 2026
U.S. Social Core Equity 2 Portfolio2,1850.02%US$2,163Jul 31, 2026
Fidelity Nasdaq Composite Index Fund2,0100.02%US$6,533May 31, 2026
Dimensional US Sustainability Core 1 ETF100<0.01%US$99Jul 31, 2026
Dimensional US Core Equity 1 ETF8<0.01%US$8Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Branham Justin Earl5.10%462KAug 21, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ted W Love
Other companies: Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past)
Director · Since at least Sep 17, 2026
Richard J. Berman
Other companies: COMSovereign Holding Corp. (Director · Since at least Jan 21, 2021); Celularity Inc. (Director · Aug 27, 2024 – Dec 19, 2024 · Past); Sidus Space, Inc. (Director · Jan 18, 2024 – Jan 18, 2024 · Past); Context Therapeutics Inc. (Director · Oct 19, 2021 – Jun 13, 2024 · Past); BioVie Inc. (Director · Sep 28, 2021 – Nov 20, 2024 · Past); Frontier Investment Corp (Director · Jun 30, 2021 – Jun 30, 2021 · Past); TraqIQ Inc (Director · Apr 5, 2021 – Apr 5, 2021 · Past); Cuentas Inc. (Director · Sep 13, 2018 – Dec 20, 2018 · Past); Catasys Inc (Director · Mar 11, 2017 – Aug 2, 2018 · Past); CryoPort, Inc. (Director · Jan 12, 2015 – May 17, 2024 · Past); MetaStat Inc (Director · Oct 15, 2014 – Mar 27, 2015 · Past); Dyadic International, Inc. (Director · Feb 10, 2006 – Jan 2, 2007 · Past); Easylink Services International Corp (Director · Jan 5, 2006 – Jul 2, 2012 · Past); Advaxis Inc (Director · Dec 31, 2005 – May 4, 2020 · Past)
Director · Nov 15, 2006 – Jan 9, 2017 · Past
Anne C. Whitaker
Other companies: Alkermes plc (Director · Since at least Sep 14, 2026); ICON plc (Director · Since at least Mar 18, 2026); OraSure Technologies, Inc. (Director · Nov 8, 2021 – May 15, 2023 · Past); Mallinckrodt Inc (Director · May 16, 2018 – Jun 16, 2022 · Past); Bausch Health Companies Inc. (EVP, Company Group Chairman · May 13, 2015 – Dec 5, 2016 · Past); Madrigal Pharmaceuticals, Inc. (President and CEO, Director · Mar 2, 2014 – Sep 3, 2014 · Past); Wolfspeed, Inc. (Director · Dec 2, 2013 – Nov 5, 2020 · Past)
Director · Nov 1, 2020 – Jan 10, 2022 · Past
Jeffrey Farrow
Other companies: Achieve Life Sciences, Inc. (Director · Since at least May 29, 2026); Tarsus Pharmaceuticals, Inc. (See Remarks · Since at least Apr 24, 2023); Global Blood Therapeutics Inc (Chief Financial Officer · Apr 4, 2016 – Oct 5, 2022 · Past); ZS Pharma Inc (Chief Financial Officer · Jul 8, 2015 – Dec 17, 2015 · Past); Hyperion Therapeutics Inc (CFO · Jul 25, 2012 – May 7, 2015 · Past); Renovis Inc (V.P., Finance and CAO · Jul 1, 2007 – May 2, 2008 · Past)
Director · Since Oct 13, 2026 · Appointed, no departure found
Michael Davidson
Other companies: BioAge Labs, Inc. (Independent Director · Since at least Mar 26, 2024); NewAmsterdam Pharma Company N.V. (Chief Executive Officer · Since at least Dec 29, 2023); Tenax Therapeutics, Inc. (Board Director · Since at least Feb 25, 2021); Silence Therapeutics PLC (Director · Jan 2, 2025 – Jan 2, 2025 · Past); Omthera Pharmaceuticals Inc (Executive VP & CMO · Apr 11, 2013 – Jul 18, 2013 · Past)
Director · Jul 28, 2020 – Jan 10, 2022 · Past
David J. Mazzo
Other companies: Palisade Bio, Inc. (Director · Jun 17, 2019 – Apr 1, 2021 · Past); Tobira Therapeutics Inc (Chief Executive Officer, Director · Aug 21, 2013 – Jan 1, 2014 · Past); EyePoint, Inc. (Director · Jul 13, 2007 – Feb 28, 2020 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – Feb 12, 2014 · Past)
President and Chief Executive Officer · Since at least Jan 5, 2015
Heidi Henson
Other companies: Perspective Therapeutics, Inc. (Director · Since at least Jun 1, 2023); PepGen Inc. (Non-Executive Director · Since at least May 5, 2022); Pardes Biosciences Inc (Chief Financial Officer · Dec 23, 2021 – Aug 31, 2023 · Past); Kura Oncology, Inc. (Chief Financial Officer · Mar 6, 2015 – Jan 24, 2018 · Past)
Director · Since at least Sep 15, 2022
Robert Dickey IV
Other companies: Vyome Holdings, Inc. (Chief Financial Officer · Since at least Aug 15, 2025); Enveric Biosciences, Inc. (Chief Financial Officer · Sep 9, 2022 – Sep 9, 2022 · Past); Emmaus Life Sciences, Inc. (Director · Jul 17, 2019 – Jul 17, 2019 · Past); AIM ImmunoTech Inc. (Chief Financial Officer · Jun 11, 2009 – Apr 4, 2022 · Past)
Chief Financial Officer · Aug 19, 2013 – Dec 31, 2014 · Past
Alan G Harris
Other companies: Radius Health, Inc. (Chief Medical Officer · Feb 21, 2014 – Dec 17, 2014 · Past); NPS Pharmaceuticals Inc (SVP, Chief Medical Officer · Jan 2, 2008 – Jan 2, 2008 · Past); TG Therapeutics, Inc. (Chief Medical Officer · Feb 1, 2006 – Apr 25, 2007 · Past)
See Remarks · Jul 6, 2009 – Apr 4, 2011 · Past
Andrew L Pecora
Other companies: Celularity Inc. (President · Sep 15, 2021 – Sep 15, 2021 · Past); Tetralogic Pharmaceuticals Corp (Director · Dec 11, 2013 – Jul 10, 2015 · Past); Cancer Genetics Inc (Director · Apr 4, 2013 – Nov 18, 2013 · Past)
Director · Jan 19, 2011 – Jun 22, 2016 · Past
All 37 people
PersonSeat
Gregory B. Brown
Other companies: Aquestive Therapeutics, Inc. (Chair of the Board, Aquestive Director and Co-founder of HealthCare Royalty Partners · Since at least Jul 24, 2018); Cambrex Corporation (Director · Oct 31, 2017 – Dec 4, 2019 · Past); Invuity Inc (Director · Jun 11, 2015 – Jun 11, 2015 · Past)
Director · Since at least Oct 10, 2016
Joshua Lehrer-Graiwer
Other companies: Fulcrum Therapeutics, Inc. (Director · Since at least Apr 23, 2026); LENZ Therapeutics, Inc. (PRESIDENT AND CEO, Director · Jan 13, 2021 – Feb 21, 2023 · Past); Global Blood Therapeutics Inc (Chief Medical Officer · Oct 1, 2019 – Mar 5, 2020 · Past)
President & COO · Since at least Sep 17, 2026
Mohammad Azab
Other companies: Durect Corporation (Director · Since at least Jan 4, 2021); Xenon Pharmaceuticals Inc. (Director · Nov 4, 2014 – Dec 19, 2023 · Past); Astex Pharmaceuticals Inc (Chief Medical Officer · Jul 21, 2009 – Oct 11, 2013 · Past)
Director · Since at least Sep 15, 2022
Peter Traber
Other companies: Cartesian Therapeutics, Inc. (Head of Research and Development · Since at least Aug 1, 2020); Galectin Therapeutics Inc. (President & CEO · Feb 12, 2009 – Jun 13, 2018 · Past); Tanox Inc (Director · Jun 2, 2006 – Jun 2, 2006 · Past)
Director · Jan 22, 2015 – Jan 10, 2022 · Past
Steven M Klosk
Other companies: Bolt Projects Holdings, Inc. (Director · Aug 13, 2024 – Nov 25, 2024 · Past); Golden Arrow Merger Corp (Director · Mar 16, 2021 – Mar 16, 2021 · Past); Cambrex Corporation (President & CEO, Director · May 3, 2016 – Dec 4, 2019 · Past)
Director · Since at least Jun 22, 2016
Cynthia L. Flowers
Other companies: Kadmon Holdings Inc (Director · Jan 22, 2019 – Nov 8, 2021 · Past); G1 Therapeutics Inc (Director · Jun 7, 2018 – Sep 18, 2024 · Past)
Director · Since at least Nov 7, 2018
Douglas W Losordo
Other companies: Cadrenal Therapeutics, Inc. (Chief Medical Officer · Jan 19, 2023 – Jan 18, 2024 · Past); Longeveron Inc. (Director · Feb 11, 2021 – Dec 21, 2023 · Past)
See Remarks · Aug 5, 2013 – Jan 13, 2020 · Past
Todd C. Girolamo
Other companies: ProKidney Corp. (Chief Legal Officer and Secretary · Since at least Jul 11, 2022); Longeveron Inc. (Director · Feb 15, 2022 – Dec 21, 2022 · Past)
CLO, SVP of Corp Dev · Jun 17, 2021 – Jan 13, 2022 · Past
Catherine M Vaczy
Other companies: Genprex, Inc. (EVP GC Chief Strategy Officer · Mar 12, 2020 – Apr 21, 2023 · Past)
General Counsel · Oct 31, 2008 – Apr 13, 2015 · Past
Jeff Farrow
Other companies: Tarsus Pharmaceuticals, Inc. (Chief Financial Officer and Chief Strategy Officer · Since at least Nov 4, 2026)
Director · Since at least Oct 14, 2026
Joseph Talamo
Other companies: Intensity Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 11, 2023)
SVP and CFO · Jan 8, 2018 – Jan 13, 2020 · Past
Martin E Schmieg
Other companies: Fibrocell Science Inc (CFO, Sr. VP · Dec 31, 2005 – Dec 31, 2005 · Past)
Vice President- Corporate Dev · Jun 25, 2012 – Jun 25, 2012 · Past
Robert S Vaters
Other companies: Orthofix Medical Inc. (President and CEO · Sep 7, 2008 – Feb 27, 2013 · Past)
President & CFO, Director · Jan 5, 2015 – Aug 12, 2015 · Past
Steven S Myers
Other companies: QuantumSphere Inc (Director · Aug 19, 2014 – May 18, 2015 · Past)
Director · Nov 16, 2006 – Jan 10, 2022 · Past
Ian ZhangSee Remarks · Sep 1, 2010 – Apr 4, 2011 · Past
James NiscoSenior Vice President, Finance and Treasury and Chief Accounting Officer · Since at least Apr 15, 2024
Jason KolbertSee Remarks · Mar 4, 2011 – Jan 4, 2012 · Past
Jian M ZhangSee Remarks · Oct 30, 2009 – Jun 9, 2010 · Past
John MendittoVice President, Investor Relations and Corporate Communications · Since at least Aug 4, 2026
Joseph ZuckermanDirector · Aug 30, 2006 – May 21, 2009 · Past
Kristen K BuckEVP, R&D and CMO · Since at least Sep 1, 2021
Mingsheng ShiSee Remarks, Director · Jun 1, 2010 – Jan 4, 2012 · Past
Renee CohenVP of Oper. & Corp. Strategy · Aug 15, 2007 – Feb 27, 2008 · Past
Robert A PretiSee Remarks, Director · Jan 19, 2011 – Apr 25, 2017 · Past
Robert DillmanSee Remarks · May 8, 2014 – May 9, 2014 · Past
Steven M. KloskDirector · Since at least Nov 4, 2026
Tariq ImamSenior Vice President, Business Development and Operations and General Counsel · Since at least Feb 3, 2025

Open People

Log in to ask 6ix AI your own questions about Lisata Therapeutics, Inc.